HT980A
TRNDi036-A
General
Cell Line |
|
hPSCreg name | TRNDi036-A |
Cite as: | TRNDi036-A (RRID:CVCL_C9LP) |
Alternative name(s) |
HT980A
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
|
Last update | 31st August 2023 |
User feedback | |
Provider |
|
Generator | NIH/NCATS-TRND Branch (TRND) |
External Databases |
|
BioSamples | SAMEA114266353 |
Cellosaurus | CVCL_C9LP |
Wikidata | Q123033652 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA114266353 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | gilbertma@chop.edu |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | gilbertma@chop.edu |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Patients were consented into an IRB-approved study at the Children’s Hospital of Philadelphia and the study team obtained written consent. |
Approval number | 92-000527 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
An immature lymphocyte that has enlarged in response to antigenic stimulation.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
Other medium:
Base medium: Stemflex
Main protein source: Serum concentration: % |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|||||
SOX2 |
Yes |
|||||
SSEA-4 |
Yes |
|||||
TRA 1-60 |
Yes |
|||||
TRA 1-81 |
Yes |
Morphology pictures
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.